Active ingredients: Atezolizumab
Tecentriq 1,200 mg concentrate for solution for infusion.
Concentrate for solution for infusion.
Clear, colourless to slightly yellowish liquid.
Each 20 mL vial of concentrate contains 1,200 mg atezolizumab*.
After dilution (see section 6.6), one mL of solution contains approximately 4.4 mg of atezolizumab.
* Atezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1) monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity.
Glacial acetic acid
Water for injections
Type I glass vial with a butyl rubber stopper and an aluminium seal with a plastic aqua flip-off cap containing 20 mL of concentrate solution for infusion.
Pack of one vial.
Roche Registration GmbH, Emil-Barell-Strasse 1, 79639, Grenzach-Wyhlen, Germany
Date of first authorisation: 21 September 2017